Madrigal Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Madrigal is a biopharmaceutical company focused on Rezdiffra (resmetirom) for noncirrhotic NASH with moderate-to-advanced fibrosis. The FDA granted Rezdiffra accelerated approval in March 2024; U.S. availability began in April. The company had no product revenue in the quarter.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $71.2 million | $62.2 million; up 15% |
| Selling, general and administrative expense | $80.8 million | $16.2 million; up 399% |
| Total operating expenses | $152.0 million | $78.3 million |
| Operating loss | $152.0 million | $78.3 million |
| Interest income / expense | $8.3 million / $3.8 million | $3.8 million / $2.3 million |
| Net loss | $147.5 million | $76.9 million |
| Basic and diluted loss per share | $7.38 | $4.23 |
| Net cash used in operating activities | $149.2 million | $84.1 million |
| Cash, cash equivalents and marketable securities | $1,059.1 million at March 31 | $634.1 million at December 31, 2023 |
| Loan principal outstanding | $115.0 million; 10.95% interest rate | Interest-only period and maturity extended following FDA approval |
Margins: Not meaningful because the company reported no revenue. The filing does not provide revenue-based margin figures.
Changes and liquidity
- Net loss increased $70.6 million year over year. SG&A rose $64.6 million, primarily due to commercial launch preparation, increased headcount and stock-based compensation. R&D increased $9.1 million, mainly from manufacturing timing, headcount and related compensation.
- Operating cash use rose by $65.1 million year over year. Investing activities provided $98.1 million, mainly reflecting maturities and sales of marketable securities, while financing activities provided $573.7 million, principally from the March public offering.
- The March offering generated approximately $574.0 million in net proceeds. The underwriters’ option closed April 2, 2024, adding approximately $85.9 million net proceeds after quarter-end. The offering included common stock and pre-funded warrants.
- Management believes available cash and investments will fund operations for more than one year from issuance of the financial statements. It cautions that future liquidity needs will be substantial and depend in part on successful commercialization.
- Cash, cash equivalents and marketable securities substantially exceed reported debt; current liabilities were $114.3 million. The company reported compliance with all loan covenants at March 31, 2024.
Outlook, risks and unusual items
- No quantitative revenue, profit or cash-flow guidance is provided. Management expects continued substantial R&D spending and expects SG&A to increase as commercialization and operating activities expand.
- Rezdiffra’s accelerated approval is subject to post-approval requirements, including verification of clinical benefit in confirmatory trials. Failure to meet commitments or obtain positive confirmatory data could lead to regulatory action, including withdrawal of approval.
- Commercial success is uncertain: Madrigal has not previously launched a product and identifies risks involving market acceptance, reimbursement, pricing, competition, manufacturing and supply, and building its commercial organization. Rezdiffra is its only approved drug.
- The loan is secured by substantially all company assets other than intellectual property. A $75 million third tranche became available after approval but remained undrawn at quarter-end and was available until June 12, 2024; another $60 million tranche is subject to lender discretion.
- A $5.0 million milestone became payable to Roche following U.S. FDA approval. Roche is also entitled to tiered single-digit royalties on net sales, subject to reductions; there were no licensed-product sales in Q1.
- Other stated risks include potential need for further financing, equity dilution or restrictive debt terms, clinical and regulatory uncertainty, and reliance on third-party manufacturers. No material legal proceedings were reported.
Most important facts for investors to verify
- Commercial launch progress after Rezdiffra became available in April, including sales, access, reimbursement and demand; Q1 revenue was zero.
- Post-approval and confirmatory-trial obligations, timelines and results, and any regulatory updates affecting accelerated approval.
- Cash burn and runway as commercialization, manufacturing, clinical programs and launch spending scale; assess the impact of the April offering proceeds.
- Potential dilution from the March offering’s pre-funded warrants and other outstanding options, restricted stock units and warrants.
- Debt terms, covenant compliance, and whether the company drew the available third loan tranche before its June 12, 2024 availability deadline.